Biosimilars are rapidly transforming the U.S. pharmaceutical market amid rising healthcare costs and a shift in interchangeability policy. Market competition is intensifying, with some biosimilars offering wholesale and ASP discounts, signaling significant cost savings and ultimately broader adoption.

Competitors in the field of adalimumab and insulin products may soon include authorized biologics.